An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

A massive drug bust in Flushing, Queens has led to the indictment of four individuals accused of running a dangerous ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...

A Colne man who lost his football scholarship in America due to a ketamine addiction is warning people about the dangers of ...